7-chloro-4-hydroxy-2-(pyrazin-2-ylmethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione methanesulfonate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-chloro-4-hydroxy-2-(pyrazin-2-ylmethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione methanesulfonate
• 英文别名: 7-Chloro-2-(pyrazin-2-ylmethyl)-3,5-dihydropyridazino[4,5-b]quinoline-1,4,10-trione;methanesulfonic acid
• 化学式: CH₄O₃S*C₁₆H₁₀ClN₅O₃
• 分子量: 451.847
• InChiKey: NHCPJDVOGIBNRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.53
• 重原子数：
  30
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  167
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-甲基吡嗪 在 过氧化苯甲酰 N-氯代丁二酰亚胺 作用下， 以 四氢呋喃 、 四氯化碳 为溶剂， 反应 13.08h， 生成 7-chloro-4-hydroxy-2-(pyrazin-2-ylmethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione methanesulfonate
  参考文献：
  名称：

  Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain

  摘要：

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.

  DOI：

  10.1021/jm060212s

文献信息

• Method and composition for the treatment of pain
  申请人：——

  公开号：US20030162783A1

  公开（公告）日：2003-08-28

  A method for the treatment of pain is disclosed comprising administration of a pain-ameliorating effective amount of any compound according to structural diagram I; 1 wherein: A, D and R 1 are as defined in the specification. Also disclosed are pharmaceutical compositions comprising a pain-ameliorating effective amount of a compound in accord with structural diagram I.

  本发明公开了一种治疗疼痛的方法，包括给予按照结构式I的任何化合物的缓解疼痛有效量；其中：A、D和R1如规范中所定义。还公开了包括按照结构式I的化合物的缓解疼痛有效量的制药组合物。
• Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain
  作者：Thomas M. Bare、Dean G. Brown、Carey L. Horchler、Megan Murphy、Rebecca A. Urbanek、Vernon Alford、Christine Barlaam、Martin C. Dyroff、James B. Empfield、Janet M. Forst、Keith J. Herzog、Richard A. Keith、Alan S. Kirschner、Chi-Ming C. Lee、Joseph Lewis、Frances M. McLaren、Kathy L. Neilson、Gary B. Steelman、Shephali Trivedi、Edward P. Vacek、Wenhua Xiao

  DOI：10.1021/jm060212s

  日期：2007.6.1

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.